These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 33796107)

  • 1. Antibody Afucosylation Augments CD16-Mediated Serial Killing and IFNγ Secretion by Human Natural Killer Cells.
    Karampatzakis A; Brož P; Rey C; Önfelt B; Cruz De Matos GDS; Rycroft D; Ambrose A; Davis DM
    Front Immunol; 2021; 12():641521. PubMed ID: 33796107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.
    Bowles JA; Wang SY; Link BK; Allan B; Beuerlein G; Campbell MA; Marquis D; Ondek B; Wooldridge JE; Smith BJ; Breitmeyer JB; Weiner GJ
    Blood; 2006 Oct; 108(8):2648-54. PubMed ID: 16825493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells.
    Capuano C; Romanelli M; Pighi C; Cimino G; Rago A; Molfetta R; Paolini R; Santoni A; Galandrini R
    Cancer Res; 2015 Oct; 75(19):4097-108. PubMed ID: 26229120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
    Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
    Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential.
    Clémenceau B; Vivien R; Pellat C; Foss M; Thibault G; Vié H
    MAbs; 2013; 5(4):587-94. PubMed ID: 23770975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity.
    Oliviero B; Mantovani S; Varchetta S; Mele D; Grossi G; Ludovisi S; Nuti E; Rossello A; Mondelli MU
    J Hepatol; 2017 Jun; 66(6):1130-1137. PubMed ID: 28192188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor VIII-Fc Activates Natural Killer Cells
    Lagassé HAD; Hopkins LB; Jankowski W; Jacquemin MG; Sauna ZE; Golding B
    Front Immunol; 2021; 12():692157. PubMed ID: 34262568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation.
    Gong Q; Hazen M; Marshall B; Crowell SR; Ou Q; Wong AW; Phung W; Vernes JM; Meng YG; Tejada M; Andersen D; Kelley RF
    MAbs; 2016; 8(6):1098-106. PubMed ID: 27216702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agonistic effects of anti-CD2 and anti-CD16 antibodies on human natural killer killing.
    Uggla CK; Geisberg M; Jondal M; Knowles RW
    Scand J Immunol; 1989 May; 29(5):507-15. PubMed ID: 2567053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
    Fujii R; Schlom J; Hodge JW
    J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies.
    Thomann M; Reckermann K; Reusch D; Prasser J; Tejada ML
    Mol Immunol; 2016 May; 73():69-75. PubMed ID: 27058641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
    Le Garff-Tavernier M; Decocq J; de Romeuf C; Parizot C; Dutertre CA; Chapiro E; Davi F; Debré P; Prost JF; Teillaud JL; Merle-Beral H; Vieillard V
    Leukemia; 2011 Jan; 25(1):101-9. PubMed ID: 20975664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity.
    Grier JT; Forbes LR; Monaco-Shawver L; Oshinsky J; Atkinson TP; Moody C; Pandey R; Campbell KS; Orange JS
    J Clin Invest; 2012 Oct; 122(10):3769-80. PubMed ID: 23006327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity.
    Zhu H; Blum RH; Bjordahl R; Gaidarova S; Rogers P; Lee TT; Abujarour R; Bonello GB; Wu J; Tsai PF; Miller JS; Walcheck B; Valamehr B; Kaufman DS
    Blood; 2020 Feb; 135(6):399-410. PubMed ID: 31856277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.
    Weitzman J; Betancur M; Boissel L; Rabinowitz AP; Klein A; Klingemann H
    Leuk Lymphoma; 2009 Aug; 50(8):1361-8. PubMed ID: 19562616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of cytolytic activity in CD3- and CD3+ killer cell clones by monoclonal antibodies (anti-CD16, anti-CD2, anti-CD3) depends on subclass specificity of target cell IgG-FcR.
    van de Griend RJ; Bolhuis RL; Stoter G; Roozemond RC
    J Immunol; 1987 May; 138(10):3137-44. PubMed ID: 2952709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer (NK) activity in human responders and nonresponders to stimulation by anti-CD16 antibodies.
    Galatiuc C; Gherman M; Metes D; Sulica A; DeLeo A; Whiteside TL; Herberman RB
    Cell Immunol; 1995 Jul; 163(2):167-77. PubMed ID: 7606790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells.
    Srpan K; Ambrose A; Karampatzakis A; Saeed M; Cartwright ANR; Guldevall K; De Matos GDSC; Önfelt B; Davis DM
    J Cell Biol; 2018 Sep; 217(9):3267-3283. PubMed ID: 29967280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.
    Iida S; Kuni-Kamochi R; Mori K; Misaka H; Inoue M; Okazaki A; Shitara K; Satoh M
    BMC Cancer; 2009 Feb; 9():58. PubMed ID: 19226457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-Targeting Anti-CD20 Antibodies Mediate
    Capuano C; Battella S; Pighi C; Franchitti L; Turriziani O; Morrone S; Santoni A; Galandrini R; Palmieri G
    Front Immunol; 2018; 9():1031. PubMed ID: 29867997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.